SEARCH

SEARCH BY CITATION

References

  • APPEL, S., KUMLE, A. & MEIER, R. (1997). Clinical pharmacodynamics of SDZ HTF 919, a new 5-HT4 receptor agonist, in a model of slow colonic transit. Clin. Pharmacol. Ther., 62, 546555.
  • AZPIROZ, F., ENCK, P. & WHITEHEAD, W.E. (2002). Anorectal functional testing: review of collective experience. Am. J. Gastroenterol., 97, 232240.
  • BAIG, M.K., ZHAO, R.H., WOODHOUSE, S.L., ABRAMSON, S., SINGH, J.J., WEISS, E.G., NOGUERAS, J.J. & WEXNER, S.D. (2002). Variability in serotonin and enterochromaffin cells in patients with colonic inertia and idiopathic diarrhoea as compared to normal controls. Colorectal. Dis., 4, 348354.
  • BARDHAN, K.D., BODEMAR, G., GELDOF, H., SCHUTZ, E., HEATH, A., MILLS, J.G. & JACQUES, L.A. (2000). A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther., 14, 2334.
  • BEARCROFT, C.P., ANDRE, E.A. & FARTHING, M.J. (1997). In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum; as segmental perfusion study. Ailment. Pharmacol. Ther., 11, 11091114.
  • BERMUDEZ, J., DUNBAR, A., SANGER, G.J. & TURNER, D.H. (1990). Stimulation of canine gastric motility by BRL 24924, a new gastric prokinetic agent. J. Gastroint. Motil., 2, 281286.
  • BEUBLER, E., KOLLAR, G., SARIA, A., BURHAVE, K. & RASK-MADSEN, J. (1989). Involvement of 5-hydroxytrypatamine, prostaglandin E2, and cyclic adenosine monophosphate in cholera toxin-induced fluid secretion in the small intestine of the rat in vivo. Gastroenterology, 96, 368376.
  • BHARUCHA, A.E., CAMILLERI, M., HAYDOCK, S., FERBER, I., BURTON, D., COOPER, S., TOMPSON, D., FITZPATRICK, K., HIGGINS, R. & ZINSMEISTER, A.R. (2000). Effects of a serotonin 5-HT (4) receptor antagonist SB207266 on gastrointestinal motor and sensory function in humans. Gut, 47, 667674.
  • BORMAN, R.A. & BURLEIGH, D.E. (1993). Evidence for the involvement of a 5-HT4 receptor in the secretory response of human small intestine to 5-HT. Br. J. Pharmacol., 110, 927928.
  • BOSE, M., NICKOLS, C., FEAKINS, R. & FARTHING, M.J.G. (2000). 5-Hydroxytryptamine and enterochromaffin cells in the irritable bowel syndrome. Gastroenterology, 118 (Suppl), A563.
  • BOURAS, E.P., CAMILLERI, M., BURTON, D.D. & MCKINZIE, S. (1999). Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut, 44, 682686.
  • BOURAS, E.P., CAMILLERI, M., BURTON, D.D., THOMFORDE, G., MCKINZIE, S. & ZINSMEISTER, A.R. (2001). Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology, 210, 354360.
  • BRADETTE, M., DELVAUX, M., STAUMONT, G., FIORAMONTI, J., BUENO, L. & FREXINOS, J. (1994). Evaluation of colonic sensory thresholds in IBS patients using a barostat. Dig. Dis. Sci., 39, 449457.
  • BUDHOO, M.R., HARRIS, R.P. & KELLUM, J.M. (1996). The role of the 5-HT3 receptor in C1-secretion in human jejunal mucosa. Eur. J. Pharmacol., 314, 109114.
  • CAMILLERI, M. (2001). Review article: tegaserod. Aliment. Pharmcol. Ther., 15, 277289.
  • CAMILLERI, M., ATANASOVA, E., CARLSON, P.J., AHMAD, U., KIM, H.J., VIRAMONTES, B.E., MCKINZIE, S. & URRUTIA, R. (2002). Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology, 123, 425432.
  • CAMILLERI, M., CHEY, W.Y., MAYER, E.A., NORTHCUTT, A.R., HEATH, A., DUKES, G.E., MCSORLEY, D. & MANGEL, A.M. (2001). A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch. Intern. Med., 161, 17331740.
  • CAMILLERI, M. & PRATHER, C.M. (1992). The irritable bowel syndrome: mechanisms and a practical approach to management. Ann. Intern. Med., 116, 10011008.
  • CANN, P.A., READ, N.W. & HOLDSWORTH, C.D. (1983). Oral domperidone: double blind comparison with placebo in the irritable bowel syndrome. Gut, 24, 11351140.
  • CHEN, J.J., LI, Z., PAN, H., MURPHY, D.L., TAMIR, H., KOEPSELL, H. & GERSHON, M.D. (2001). Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: abnormal intestinal motility and the expression of cation transporters. J. Neurosci., 21, 63486361.
  • CHEN, J.X., PAN, H., ROTHMAN, T.P., WADE, P.R. & GERSHON, M.D. (1998). Guinea pig 5-HT transporter: cloning, expression, distribution, and function in intestinal sensory reception. Am. J. Phisiol., 275, G433G448.
  • CHEY, W.D. (2003). Tegaserod and other serotonergic agents: what is the evidence Rev. Gastroenterol. Disord., 2 (3), S35S40.
  • COFFIN, B., FARMACHIDI, J.P., RUEEGG, P., BASTIE, A. & BOUHASSIRA, D. (2003). Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment. Pharmacol. Ther., 17, 577585.
  • COOK, I.J., VAN EEDEN, A. & COLLINS, S.M. (1987). Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology, 93, 727733.
  • COOKE, H.J. (2000). Neurotransmitters in neuronal reflexes regulating intestinal secretion. Ann. N.Y. Acad. Sci., 915, 7780.
  • COOKE, J.G., SIDHU, M. & WANG, Y.Z. (1997). Activation of 5-HTP receptors on submucosal afferents subsequently triggers VIP neurons and chloride secretion in the guinea-pig colon. J. Autonom. Nerv. Syst., 66, 105110.
  • COREMANS, G., KERSTENS, R., DE PAUW, M. & STEVENS, M. (2003). Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion, 67, 8289.
  • CRAIG, D.A. & CLARKE, D.E. (1990). Pharmacological characterization of a neuronal receptor for 5-hydroxytryptamine in guinea pig ileum with properties similar to the 5-hydroxytryptamine 4 receptor. J. Pharmacol. Exp. Ther., 252, 13781386.
  • CROWELL, M.D. (2001). The role of serotonin in the pathophysiology of irritable bowel syndrome. Am. J. Manag. Care, 7 (8 Suppl), S252S260.
  • DEGEN, L., MATZINGER, D., MERZ, M., APPEL-DINGEMANSE, S., OSBORNE, S., LUCHINGER, S., BERTOLD, R., MAECKE, H. & BEGLINGER, C. (2001). Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment. Pharmacol. Ther., 15, 17451751.
  • DELVAUX, M., LOUVEL, D., MARMET, J.P., CAMPOS-ORIOLA, R. & FREXINOS, J. (1998). Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Ailment. Pharmacol. Ther., 12, 849855.
  • DE PONTI, F. & TONINI, M. (2001). Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs, 61, 317332.
  • DROSSMAN, D.A. (1999). Review article: an integrated approach to the irritable bowel syndrome. Aliment. Pharmacol. Ther., 13 (Suppl 2), 314.
  • DROSSMAN, D.A. & THOMPSON, W.G. (1992). The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann. Intern. Med., 116, 10091016.
  • EDWARDS, C.A., HOLDEN, S., BROWN, C. & READ, N.W. (1987). Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects. Gut, 28, 1316.
  • EL-SALHY, M., NORRGARD, O. & SPINNELL, S. (1999). Abnormal colonic endocrine cells in patients with chronic idiopathic slow-transit constipation. Scand. J. Gastroenterol., 34, 10071011.
  • EMMANUEL, A.V., KAMM, M.A., ROY, A.J. & ANTONELLI, K. (1998). Effect of a novel prokinetic drug, RO93877, on gastrointestinal transit in healthy volunteers. Gut, 42, 511516.
  • FARUP, P.G., HOVDENAK, N., WETTERHUS, S., LANGE, O.J., HOVDE, O. & TRONDSTAD, R. (1998). The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. Scand. J. Gastroenterol., 33, 128131.
  • FDA Consumer (2003) 37, 2.
  • FIELDING, J.F. (1982). Domperidone treatment in the irritable bowel syndrome. Digestion, 23, 125127.
  • FIORAMONTI, J., MILLION, M. & BUENO, L. (2000). Investigations on a 5HT4 agonist (SDZ HTF 919) and its main metabolite in conscious dogs: effects on gastrointestinal motility and impaired gastric emptying. Gastroenterology, 114, A752.
  • FORD, A.P.D.W. & CLARKE, D.E. (1993). The 5-HT4-receptor. Med. Res. Rev., 13, 633662.
  • GERSHON, M.D. (1999a). Roles played by 5-hydroxytrptamine in the physiology of the bowel. Ailment. Pharmacol. Ther., 13 (Suppl 2), 1530.
  • GERSHON, M.D. (1999b). The enteric nervous system: a second brain. Hosp. Pract., 34, 31–32, 35–38, 4142.
  • GOLDBERG, P.A., KAMM M.A SETTI-CARRARO, P., VAN DEN SIJP, J.R. & ROTH, C. (1996). Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion, 57, 478483.
  • GORE, S., GILMORE, I.T., HAIGH, C.G., BROWNLESS, S.M., STOCKDALE, H. & MORRIS, A.L. (1990). Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytrptamine receptor (type 3) antagonist. Ailment. Pharmacol. Ther., 4, 139144.
  • GOYAL, R.K. & HIRANO, I. (1996). Review article: the enteric nervous system. N. Engl. J. Med., 334, 11061115.
  • GRIDER, J.R., FOXX-ORENSTEIN, A.E. & JIN, J.G. (1998). 5-Hydroxytryptamine 4 receptor agonist initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology, 115, 370380.
  • GRUNDY, D. (2002). Towards a reduction of rectal pain Neurogastroenterol. Motil., 14, 217219.
  • GULLIKSON, G.W., LOEFFLER, R.F. & VIRINA, M.A. (1991). Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs. J. Pharmacol. Exp. Ther., 258, 103110.
  • GULLIKSON, G.W., VIRINA, M.A., LOEFFLER, R.F., YANG, D.C., GOLDSTEIN, B., WANG, S.X., MOUMMI, C., FLYNN, D.L. & ZABROWSKI, D.L. (1993). SC-49518 enhances gastric emptying of solid and liquid meals and stimulates gastrointestinal motility in dogs by a 5-hydroxytryptamin 4 receptor mechanism. J. Pharmacol. Exp. Ther., 264, 240264.
  • HANSEN, M.B. (2003a). The enteric nervous system III: a target for pharmacological treatment. Pharmacol. Toxicol., 93, 113.
  • HANSEN, M.B. (2003b). Neurohumoral control of gastrointestinal motility. Physiol. Res., 52, 130.
  • HARGREAVES, A.C., LUMMIS, S.C. & TAYLOR, C.W. (1994). Ca2+ permeability of cloned and native 5-hydroxytryptamine type 3 receptors. Mol. Pharmacol., 46, 11201128.
  • HARRAF, F., SCHMULSON, M., SABA, L., NIAZI, N., FASS, R., MUNAKATA, J., DIEHL, D., MERTZ, H., NALIBOFF, B. & MAYER, E.A. (1998). Subtypes of constipation predominant irritable bowel syndrome based on rectal perception. Gut, 43, 388394.
  • HOUGHTON, L.A., FOSTER, J.M. & WHORWELL, P.J. (2000). Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers. Aliment. Pharmacol. Ther., 14, 775782.
  • HUGE, A., ZITTEL, T.T., KREIS, M.E., BECKER, H.D. & JEHLE, E.C. (2000). Effects of Tegaserod (HTF919) on gastrointestinal motility and transit in awake rats. Gastroenterology, 118, A403.
  • KAMM, M.A. (2002). Review article: the complexity of drug development for irritable bowel syndrome. Aliment. Pharmacol. Ther., 16, 343351.
  • KIRCHGESSNER, A.L., MAWE, G.M. & GERSHON, M.D. (1990). Evaluation of the activity of chemically identified enteric neurons through the histochemical demonstration of cytochrome oxidase. J. Comp. Neurol., 301, 114.
  • KOZLOWSKI, C.M., GREEN, A., GRUNDY, D., BOISSONADE, F.M. & BOUNTRA, C. (2000). The 5-HT3 receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut, 46, 474480.
  • KREVSKY, B., MALMUD, L.S., MAURER, A.H., SOMERS, M.B., SIEGEL, J.A. & FISHER, R.S. (1987). The effect of oral cisapride on colonic transit. Aliment. Pharmacol. Ther., 1, 293304.
  • LEMBO, T., WRIGHT, R.A., BAGBY, B., DECKER, C., GORDON, S., JHINGRAN, P., CARTER, E. & Lotronex Investigator Team (2001). Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol., 96, 26622670.
  • LINDEN, D.R., CHEN, J.X., GERSHON, M.D., SHARKEY, K.A. & MAWE, G.M. (2003). Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am. J. Physiol. Gastrointest. Liver. Physiol., 285, G20716.
  • LINDEN, D.R., MOSES, P.L., BANNON, C., CROWELL, M.D., SHARKEY, K.A. & MAWE, G.M. (2002). Colonic serotonin signalling is altered in IBD and IBS. Neurogastroenterol. Motil., 14, 436437.
  • MEULEMANS, A.L. & SCHUURKES, J.A.J. (1992). Is the action of cisapride on the guinea pig ileum mediated via 5HT-4 receptors Eur. J. Pharmacol., 212, 5159.
  • MILO, R. (1980). Use of the peripheral dopamine antagonists, domperidone, in the management of gastrointestinal symptoms in patients with the irritable bowel syndrome. Curr. Med. Res. Opin., 6, 577584.
  • MIWA, J., ECHIZEN, H., MATSUEDA, K. & UMEDA, N. (2001). Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion, 63, 188194.
  • MOSES, P.L., BANNON, C., LINDEN, D.R., CROWELL, M.D., SHARKEY, K.A. & MAWE, G.M. (2002). Evidence for altered serotonin signalling in IBD and constipation predominant IBS. Am. J. Gastroenterol., 97, S274.
  • MOSS, H.E. & SANGER, G.J. (1990). The effects of granisetron, ICS 205-930, and odansetron in the visceral pain reflex induced by duodenal distension. Br. J. Pharmacol., 100, 497501.
  • MOURAD, F.H. & NASSAR, C.F. (2000). Effect of vasoactive intestinal polypeptide (CIP) antagonism on rat jejunal fluid and electrolyte secretion induced by cholera and Escherichia coli enterotoxins. Gut, 47, 382386.
  • MULLER-LISSNER, S., KOCH, G., TALLEY, N.J., DROSSMAN, D., RUEEGG, P., DUNGER-BALDAUF, C. & LEFKOWITZ, M. (2003). Subject's Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials. J. Clin. Epidemiol., 56, 310316.
  • MULLER-LISSNER, S.A. (1987). Treatment of chronic constipation with cisapride and placebo. Gut, 28, 10331038.
  • MULLER-LISSNER, S.A., FUMAGALLI, I., BARDHAN, K.D., PACE, F., PECHER, E., NAULT, B. & RUEGG, P. (2001). Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment. Pharmacol. Ther., 15, 16551666.
  • ORR, W.C., CROWELL, M.D., LIN, B., HARNISH, M.J. & CHEN, J.D. (1997). Sleep and gastric function in irritable bowel syndrome: derailing the brain–gut axis. Gut, 41, 390393.
  • PAN, H. & GERSHON, M.D. (2000). Activation of intrinsic afferent pathways in submucosal ganglia of the guinea pig small intestines. J. Neurosci., 20, 32953309.
  • POEN, A.C., FELT-VERSMA, R.J., VAN DONGEN, P.A. & MEUWISSEN, S.G. (1999). Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Ailment. Pharmacol. Ther., 13, 14391497.
  • PRATHER, C.M., CAMILLERI, M., ZINSMEISTER, A.R., MCKINZIE, S. & THOMFORDE, G. (2000). Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology, 118, 463468.
  • PRINS, N.H., BRIEJER, M.R., VAN BERGEN, P.J., AKKERMANS, L.M. & SCHUURKES, J.A. (1999). Evidence for 5-HT7 receptors mediating relaxation of human colonic circular smooth muscle. Br. J. Pharmacol., 128, 849852.
  • PRIOR, A., MAXTON, D.G. & WHORWELL, P.J. (1990). Anorectal manometry in irritable bowel syndrome: differences between diarrhea and constipation predominant subjects. Gut, 31, 458462.
  • PRIOR, A. & READ, N.W. (1993). Reduction of rectal sensitivity and post-prandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Ailment. Pharmacol. Ther., 7, 175180.
  • RAGNARSSON, G. & BODEMAR, G. (1998). Pain is temporarily related to eating but not to defecation in the irritable bowel syndrome (IBS). ‘Patients’ description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur. J. Gastroenterol. Hepatol., 10, 415421.
  • RAGNARSSON, G. & BODEMAR, G. (1999). Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples. Scand. J. Gastroenterol., 34, 9931000.
  • REY, E., ALVAREZ SANCHEZ, A. & DIAZ-RUBIO, M. (2002). Which is the best distension protocol to study rectal sensitivity in the irritable bowel syndrome Rev. Esp. Enferm. Dig., 94, 211220.
  • RITCHIE, J. (1973). Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut, 14, 125132.
  • SCHIKOWSKI, A., THEWISSEN, M., MATHIS, C., ROSS, H.G. & ENCK, P. (2002). Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol. Motil., 14, 221227.
  • SCHUTZE, K., BRANDSTATTER, G., DRAGOSICS, B., JUDMAIER, G. & HENTSCHEL, E. (1997). Double-blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome. Aliment. Pharmacol. Ther., 11, 387394.
  • SIMRÉN, M., ABRAHAMSSON, H. & BJÖRNSSON, E.S. (2001). An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut, 48, 2027.
  • SLATER, B.J., PLUSA, S.M., SMITH, A.N. & VARMA, J.S. (1997). Rectal hypersensitivity in the irritable bowel syndrome. Int. J. Colorectal Dis., 12, 2932.
  • SPILLER, R.C. (2001). Effects of serotonin on intestinal secretion and motility. Curr. Opin. Gastroenterol., 17, 99103.
  • SPILLER, R.C. (2002). Serotonergic modulating drugs for functional gastrointestinal diseases. Br. J. Clin. Pharmacol., 54, 1120.
  • SPILLER, R.C., JENKINS, D., THORNLEY, J.P., HEBDEN, J.M., WRIGHT, T., SKINNER, M. & NEAL, K.R. (2000). Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut, 47, 804811.
  • STACHER, G. (2001). Cilansetron. Curr. Opin. Investig. Drugs, 2, 14321436.
  • STEADMAN, C.H., TALLEY, N.J., PHILLIPS, S.F. & ZINSMEISTER, A.R. (1992). Selective 5-hydroxtryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome. A pilot study. Mayo Clin. Proc., 67, 732738.
  • STEENS, J., VAN DER SCHAAR, P.J., PENNING, C., BRUSSEE, J. & MASCLEE, A.A. (2002). Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol. Motil., 14, 241247.
  • STONER, M.C., ARUNCI, J.C. & LEE, J. et al. (1999). A selective 5HT4 agonist induces CAMP mediated Cl-flux from rat colonocytes. Gastroenterology, 116, A648.
  • STONER, M.C., SCHERR, A.M., LEE, J.A. & WOLFE KELLUM, J.M. (2000). Nitric oxide is a neurotransmitter in the chloride secretory response to serotonin in rat colon. Surgery, 128, 240245.
  • TALLEY, N.J. (1992). Review article: 5-hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment. Pharmacol. Ther., 6, 273289.
  • TALLEY, N.J., PHILLIPS, S.F., HADDAD, A., MILLER, L.J., TWOMEY, C., ZINSMEISTER, A.R., MACCARTY, R.L. & CIOCIOLA, A. (1990). GR 38032F (Ondansetron), a selective 5HT receptor antagonist, slows colonic transit in healthy man. Digest. Dis. Sci., 35, 477480.
  • TANIYAMA, K., NAKAYAMA, S., TAKEDA, K., MATSUYAMA, S., SHIRAKAWA, J., SANO, I. & TANAKA, C. (1991). Cisapride stimulates motility of the intestine via the 5-hydroxytryptamine receptors. J. Pharmacol. Exp. Ther., 258, 10981104.
  • THOMPSON, W.G., LONGSTRETH, G.F., DROSSMAN, D.A., HEATON, K.W., IRVINE, E.J. & MULLER-LISSNER, S.A. (1999). Functional bowel disorders and functional abdominal pain. Gut, 45 (Suppl II), II43II47.
  • TULADHAR, B.R., GE, L. & NAYLOR, R.J. (2003). 5-HT7 receptors mediate the inhibitory effect of 5-HT on peristalsis in the isolated guinea-pig ileum. Br. J. Pharmacol., 138, 12101214.
  • TURVILL, J.L., CONNOR, P. & FARTHING, M.J. (2000). The inhibition of cholera toxin-induced 5-HT release by the 5-HT(3) receptor antagonist, granisetron, in the rat. Br. J. Pharmacol., 130, 10311036.
  • VAN OUTRYVE, M., MILO, R., TOUSSAINT, J. & VAN EEGHEM, P. (1991). ‘Prokinetic’ treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. J. Clin. Gastroenterol., 12, 4957.
  • VIRAMONTES, B., MCKINZIE, S., PARDI, D.S., BURTON, D., THOMFORDE, G.M. & CAMILLERI, M. (2000). Alosetron retards small bowel and overall colonic transit in diarrhea-predominant irritable bowel syndrome (D-IBS). Gastroenterology, 118, A848.
  • VIRAMONTES, B.E., CAMILLERI, M., MCKINZIE, S., PARDI, D.S., BURTON, D. & THOMFORDE, G.M. (2001). Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol., 96, 26712676.
    Direct Link:
  • WADE, P.R., CHEN, J., JAFFE, B., KASSEM, I.S., BLAKELY, R.D. & GERSHON, M.D. (1996). Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J. Nueorsci., 16, 23522364.
  • WAPNIR, R.A. & TEICHBERG, S. (2002). Regulation mechanisms of intestinal secretion: implications in nutrient absorption. J. Nutr. Biochem., 13, 190199.
  • WHITEHEAD, W.E., ENGEL, B.T. & SCHUSTER, M.M. (1980). Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig. Dis. Sci., 25, 404413.
  • WHITEHEAD, W.E., PALSSON, O. & JONES, K.R. (2002). Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications Gastroenterology, 122, 11401156.
  • WOLFE, M. (1993). Gastrointestinal Pharmacology. London: W.B Saunders Company: Philadelphia, pp. 124.
  • ZHAO, R., BAIG, M.K., WEXNER, S.D., CHEN, W., SINGH, J.J., NOGUERAS, J.J. & WOODHOUSE, S. (2000). Enterochromaffin and serotonin cells are abnormal for patients with colonic inertia. Dis. Colon. Rectum, 43, 858863.